IQVIA Holdings Inc. provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order to life science companies, and investment and financial sectors that deal with life science companies; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level to pharmaceutical sales organizations. The Research & Development Solutions segment offers biopharmaceutical development services comprising project management and clinical monitoring, clinical trial support, and strategic planning and design services, as well as clinical trial, genomic, and bioanalytical laboratory services. The Integrated Engagement Services segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. The company serves pharmaceutical, biotechnology, device and diagnostic, and healthcare companies. IQVIA Holdings Inc. has a strategic alliance with MuleSoft, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryN/A
SectorBusiness Services
Phone919-998-2000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$9.74 billion
Profitability
Miscellaneous
Employees55,000
OptionableOptionable
Iqvia (NYSE:IQV) Frequently Asked Questions
What is Iqvia's stock symbol?
Iqvia trades on the New York Stock Exchange (NYSE) under the ticker symbol "IQV."
How were Iqvia's earnings last quarter?
Iqvia Holdings Inc (NYSE:IQV) announced its earnings results on Monday, October, 22nd. The medical research company reported $1.42 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.39 by $0.03. The medical research company earned $2.59 billion during the quarter, compared to analysts' expectations of $2.58 billion. Iqvia had a net margin of 12.29% and a return on equity of 13.69%. The company's revenue for the quarter was up 5.2% compared to the same quarter last year. View Iqvia's Earnings History.
When is Iqvia's next earnings date?
What price target have analysts set for IQV?
16 Wall Street analysts have issued 12-month target prices for Iqvia's stock. Their forecasts range from $120.00 to $150.00. On average, they anticipate Iqvia's stock price to reach $139.2857 in the next twelve months. This suggests a possible upside of 10.7% from the stock's current price. View Analyst Price Targets for Iqvia.
What is the consensus analysts' recommendation for Iqvia?
16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iqvia in the last year. There are currently 2 hold ratings, 12 buy ratings and 2 strong buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iqvia.
Has Iqvia been receiving favorable news coverage?
News stories about IQV stock have been trending negative recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Iqvia earned a news sentiment score of -2.1 on InfoTrie's scale. They also assigned press coverage about the medical research company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the stock's share price in the immediate future.
Who are some of Iqvia's key competitors?
Some companies that are related to Iqvia include Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), Exelixis (EXEL), PRA Health Sciences (PRAH), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), STARPHARMA HOLD/S (SPHRY), Sorrento Therapeutics (SRNE), Pieris Pharmaceuticals (PIRS), Luna Innovations (LUNA), Anavex Life Sciences (AVXL) and Senomyx (SNMX).
Who are Iqvia's key executives?
Iqvia's management team includes the folowing people:
- Mr. Ari Bousbib, Chairman, CEO & Pres (Age 58)
- Mr. Michael R. McDonnell, Exec. VP & CFO (Age 55)
- Mr. W. Richard Staub III, Pres of R&D Solutions (Age 56)
- Mr. Kevin C. Knightly, Pres of Information & Technology Solutions (Age 58)
- Mr. Emmanuel N. Korakis, Corp. Controller & Principal Accounting Officer (Age 45)
Who are Iqvia's major shareholders?
Iqvia's stock is owned by a variety of of retail and institutional investors. Top institutional investors include USS Investment Management Ltd (0.91%), Arvest Bank Trust Division (0.11%), Strs Ohio (0.08%), Bank of Montreal Can (0.07%), Howard Capital Management (0.06%) and DNB Asset Management AS (0.06%). Company insiders that own Iqvia stock include Ari Bousbib, Canada Pension Plan Investment, Cpp Investment Board Private H, Dennis B Ph D Gillings, Group Holdings (Sbs) Advis Tpg, Jack M Greenberg, James H Erlinger III, John Connaughton, John G Danhakl, Kevin C Knightly, Michael J Evanisko, Michael R Mcdonnell, Robert Parks and Ronald A Rittenmeyer. View Institutional Ownership Trends for Iqvia.
Which major investors are selling Iqvia stock?
IQV stock was sold by a variety of institutional investors in the last quarter, including Retirement Systems of Alabama, Bank of Montreal Can, Nisa Investment Advisors LLC, Gulf International Bank UK Ltd, Meeder Asset Management Inc., Beacon Financial Group, State of Alaska Department of Revenue and First Hawaiian Bank. Company insiders that have sold Iqvia company stock in the last year include Ari Bousbib, Canada Pension Plan Investment, Cpp Investment Board Private H, Group Holdings (Sbs) Advis Tpg, James H Erlinger III, John Connaughton, John G Danhakl, Kevin C Knightly, Michael J Evanisko, Michael R Mcdonnell, Robert Parks and Ronald A Rittenmeyer. View Insider Buying and Selling for Iqvia.
Which major investors are buying Iqvia stock?
IQV stock was acquired by a variety of institutional investors in the last quarter, including USS Investment Management Ltd, Strs Ohio, Blackcrane Capital LLC, Assenagon Asset Management S.A., First Citizens Bank & Trust Co., Appleton Partners Inc. MA, Chesley Taft & Associates LLC and Altfest L J & Co. Inc.. View Insider Buying and Selling for Iqvia.
How do I buy shares of Iqvia?
Shares of IQV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Iqvia's stock price today?
One share of IQV stock can currently be purchased for approximately $125.80.
How big of a company is Iqvia?
Iqvia has a market capitalization of $25.17 billion and generates $9.74 billion in revenue each year. The medical research company earns $1.31 billion in net income (profit) each year or $4.36 on an earnings per share basis. Iqvia employs 55,000 workers across the globe.
What is Iqvia's official website?
How can I contact Iqvia?
Iqvia's mailing address is 83 WOOSTER HEIGHTS ROAD, DANBURY CT, 06810. The medical research company can be reached via phone at 919-998-2000 or via email at [email protected]
MarketBeat Community Rating for Iqvia (NYSE IQV)
MarketBeat's community ratings are surveys of what our community members think about Iqvia and other stocks. Vote "Outperform" if you believe IQV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IQV will underperform the S&P 500 over the long term. You may vote once every thirty days.
